BioSpace News Archive

In an effort to extend cash flow through 2025, Bolt Biotherapeutics announced it is shifting its priorities to focus on two immune-stimulating antibody conjugates (ISAC) programs.

This week’s Movers & Shakers include Scribe, Appia Bio, Chimerix and KemPharm, all announcing new VP roles. Companies also plan for the future with the implementation of a succession plan.

The makers of ranitidine-based products, such as Sanofi, GSK and Haleon, are reeling from lawsuits related to carcinogenic contamination that could result in billions of dollars in damages.

Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.

A new study on Alzheimer’s disease ties the brain’s immune response to the condition, while scientists have identified a better antibody treatment for cancer and more research news.

Centessa halted ZF874 following the report of an adverse event that involved elevated liver enzymes in a Phase I study. This is the second development program the company has stopped in as many months.

In a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.

MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.

Vyne Therapeutics’ combination therapy for atopic dermatitis failed to meet the primary endpoint in a Phase II trial, leaving the company evaluating its priorities and pipeline.

Wilmington, Delaware, United States, Transparency Market Research Inc. – Applications of expression vectors in the R&D of biopharmaceutical and biomedical products are expected to be considered the key factors augmenting the growth of the global expression vectors market during the forecast period set between 2021 and 2031.